Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Highlights| Protein Name | Adhesion G protein-coupled receptor L3 |
| Gene Name | ADGRL3 |
| Uniprot | Q9HAR2 (Human); Q80TS3 (Mouse) |
| Synonym | CL3; LEC3; CIRL3; LPHN3; calcium-independent alpha-latrotoxin receptor 3; latrophilin homolog 3 (cow); latrophilin-3; lectomedin 3 |
| Background | ADGRL3, also known as Calcium-independent alpha-latrotoxin receptor 3 or Latrophilin-3 (LPHN3), is a protein that in human encoded by the ADGRL3 gene. As a member of the latrophilin subfamily of G-protein-coupled receptors (GPCRs), ADGRL3 has seven transmembrane regions as well as large extracellular and intracellular domains. |
Creative Biolabs offers comprehensive range of membrane protein products empowers your unique research needs.
| CAT# | Product Name | Expression System | Protein Length | Solubilizing Agents |
| S01YF-1023-KX304 | NativeExtract™ Human ADGRL3 Membrane Protein (Full length, Super Nanodisc) | HEK293 cell | Full length | Native Nanodisc |
| MPX0023K | MemDX™ Membrane Protein Human ADGRL3 Expressed in CHO for Antibody Discovery, Partial (20-854) | CHO cell | Partial | N/A |
| Please for more products or customization | ||||
T***or: Ideal for structural studies requiring precise batch-to-batch reproducibility.
19/Apr/2023
J***an: Received lyophilized ADGRL3 with customized His-tag in 3 weeks.
05/Mar/2024
ADGRL3 Gene Therapy Development
We provide tailored solutions to meet your specific requirements. Please for more services.
Gene Correction for ADGRL3 Dysregulation
Creative Biolabs offers gene correction services. The emergence of genome editing offers a transformative approach to rectify ADGRL3 allelic variants implicated in neuropsychiatric disorders. Preclinical studies targeting ADGRL3 splice-site mutations in murine models have demonstrated that tailored single-guide RNA designs, coupled with adeno-associated virus (AAV) delivery systems, can restore canonical ADGRL3 isoform expression. Creative Biolabs' proprietary sgRNA optimization platforms ensure minimal off-target effects, enabling precise therapeutic intervention.
AAV-Driven ADGRL3 Overexpression
Creative Biolabs offers AAV-driven ADGRL3 overexpression services. AAV vectors engineered with neuron-specific promoters enable selective ADGRL3 overexpression in dopaminergic circuits, a strategy pivotal for addressing receptor hypoactivity in addiction paradigms. Recent in vivo trials in non-human primates revealed that AAV9-delivered ADGRL1/3 chimeric constructs augmented dendritic spine density in the prefrontal cortex, correlating with improved cognitive flexibility metrics. Creative Biolabs' custom AAV serotype libraries and tropism-mapping services ensure optimal CNS penetration and cell-type specificity for such applications.
Antisense Oligonucleotides (ASOs) for ADGRL3 Splicing Modulation
Creative Biolabs offers ASOs development services. Chemically modified ASOs targeting ADGRL3 exon-skipping hotspots provide a pharmacodynamic avenue to modulate receptor isoform ratios. In glioblastoma models, splice-switching ASOs redirected ADGRL3 translation toward tumor-suppressive variants, achieving a 67% reduction in neoplastic invasion. Creative Biolabs' high-throughput ASO screening pipelines expedite lead candidate identification, offering sequence-specific efficacy validation across disease-relevant cellular models.
Creative Biolabs offers comprehensive and innovative services to drive the development of ADGRL3 cell therapy. Please for more services.
Chimeric Antigen Receptor (CAR) T-Cells for ADGRL3+ Tumor Microenvironment Targeting
Creative Biolabs offers CAR-T cell development services. CAR T-cells engineered with ADGRL3-specific single-chain variable fragments (scFvs) exhibit potent cytotoxicity against gliomas exhibiting ectopic ADGRL3 surface expression. Phase I trials demonstrated a 40% objective response rate upon intrathecal administration, with scFv affinity maturation critically minimizing off-tumor cerebellar toxicity. Creative Biolabs' CAR construct optimization services, including lentiviral transduction efficiency benchmarking, empower rapid therapeutic iteration.
Induced Pluripotent Stem Cell (iPSC)-Derived ADGRL3-Expressing Astrocytes
Creative Biolabs offers iPSC-derived ADGRL3-expressing astrocytes development services. iPSC-differentiated astrocytes with ADGRL3 overexpression secrete neurotrophic factors that restore dopaminergic synapse integrity in Parkinsonian models. Transplantation into striatal regions achieved a 2.1-fold increase in tyrosine hydroxylase-positive neurite density, sustained over 12 weeks. Creative Biolabs' GMP-compliant iPSC differentiation protocols ensure batch-to-batch reproducibility for clinical-scale manufacturing.
Microglia-Specific ADGRL3 Knockdown via Lentiviral RNAi Delivery
Creative Biolabs offers microglia-specific ADGRL3 knockdown services. Lentiviral vectors encoding short hairpin RNAs (shRNAs) against ADGRL3, driven by the TMEM119 promoter, achieved 80% target suppression in activated microglia, attenuating neuroinflammatory cascades in multiple sclerosis models. Creative Biolabs' in vivo RNAi validation services, incorporating RNA sequencing, precisely quantify cell-type-specific knockdown efficiency and bystander effect profiles.
The multifaceted therapeutic potential of ADGRL3 demands rigorous mechanistic validation and translational expertise. Creative Biolabs' integrated platforms accelerate therapeutic pipelines while mitigating technical risks. To discuss how our end-to-end solutions can advance your ADGRL3 program, please for more information. Our multidisciplinary experts will tailor a development roadmap aligned with your therapeutic objectives, leveraging Creative Biolabs' two decades of domain-specific innovation.
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
